P53 and PET羊elated parameters as a prognostic factor of head and neck carcinoma treated by chemoradiation

P53和PET相关参数作为头颈癌放化疗预后因素

• 批准号: 21592193
• 负责人: INOHARA Hidenori
• 金额: $ 2.83万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21592193/
• 关键词: 頭頸部扁平上皮癌; 化学放射線同時併用療法; p53コドン72遺伝子多型; p53遺伝子変異; ヒトパピローマウイルス; SUVmax; SUVmean; metabolic tumor volume; 頭頸部癌; 科学放射線同時併用療法

Prognostic significance of p53 codon72 polymorphism, p503 mutations. human papillomavirus, and pretreatment PET parameters, in addition to clinical factors, were prospectively addressed in patients with locoreginally advanced head and neck sqamous cell carcinoma treated by concurrent chemoradiotherapy. Pretreatment PET parameters include SUVmax. SUVmean, and metabolic tumor volume of a primary tumor. Multivariatc analysis revealed that MTV is only an independent prognostic factor. Overall survival as well as laryngectomy survival were significantly better in patients with low MTV tumor than in those with high MTV tumor.

P53基因72位密码子多态性、p503突变对预后的意义在接受同步放化疗的晚期头颈部鳞状细胞癌患者中，除了临床因素外，前瞻性地研究了人乳头瘤病毒和治疗前的PET参数。前处理的PET参数包括SUVmax。SUV平均值和原发肿瘤的代谢肿瘤体积。多因素分析显示，MTV仅是一个独立的预后因素。低MTV肿瘤患者的总体存活率和喉切除术存活率明显好于高MTV肿瘤患者。

项目成果

頭頸部診療癌におけるPETの有用性

PET 在头颈癌治疗中的应用

• 发表时间: 2011
• 作者: 三輪高喜;志賀英明;木下弥生;広田京子;土田明日香;古川仭;猪原秀典
• 通讯作者: 猪原秀典